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 Abstract 
 
Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and 
oral anticoagulation therefore is the essential part of AF management to reduce the risk of 
this complication. Until recently, the vitamin K antagonists (VKAs, e.g. warfarin) were the 
only oral anticoagulants available, acting by decreased synthesis of vitamin K-dependent 
coagulation factors (II, VI, IX, and X). The VKAs had many limitations: delayed onset and 
prolonged offset of action, variability of anticoagulant effect among patients, multiple food 
and drug interactions affecting pharmacological properties of warfarin, narrow therapeutic 
window, obligatory regular laboratory control, which all made warfarin ‘inconvenient’ both 
for patients and clinicians. The limitations of VKAs led to development of new class of drugs 
collectively defined as non-VKA oral anticoagulants (NOACs), which included direct thrombin 
inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban). The 
NOACs avoid many of the VKA drawbacks. In this review, we will focus on the current 
evidence justifying use of NOACs in non-valvular AF. 
 
Key words: atrial fibrillation, non-vitamin K oral anticoagulants, dabigatran, rivaroxaban, 
apixaban, edoxaban, warfarin 
  
 Introduction 
 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which confers an 
increased risk of stroke and other thromboembolic events. Oral anticoagulation therefore is 
the essential part of AF management to reduce the risk of these complications, irrespective 
of AF type (paroxysmal, persistent, or permanent).1,2 The diagnosis of AF has improved 
dramatically during past years with various up to date arrhythmia screening technologies 
became available, allowing detection of asymptomatic and rare AF episodes in substantial 
proportion of patients, and appropriate stroke prophylaxis is also required in this group.3,4 
 
Until recently, the vitamin K antagonists (VKAs, e.g. warfarin) were the only oral 
anticoagulants available, acting by decreased synthesis of vitamin K-dependent coagulation 
factors (II, VI, IX, and X; see Figure 1) by inhibition of VKORC1 (vitamin K epoxide reductase 
complex subunit 1), which is essential enzyme for vitamin K turnover in the human body.5 
The VKAs have many limitations: delayed onset and prolonged offset of action, variability of 
anticoagulant effect among patients, multiple food and drug interactions affecting 
pharmacological properties of warfarin, narrow therapeutic window, obligatory regular 
laboratory control, broad targets of action (e.g. warfarin interferes with synthesis of other 
than coagulation factors vitamin K dependent proteins and eventually may lead to 
development of soft tissues calcification, osteoporosis, skin necrosis), which all make 
warfarin ‘inconvenient’ both for patients and clinicians. The variability of anticoagulant 
effect among patients results from genetic polymorphism of VKORC1 and several other 
genes. Regular laboratory monitoring is obligatory to maintain the INR within 2.0-3.0, and to 
ensure a high time in therapeutic range (TTR).5 
  
The limitations of VKAs led to development of new class of drugs collectively defined as non-
VKA oral anticoagulants (NOACs, previously referred to as new or novel OACs6), which 
included direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, 
apixaban, edoxaban) that avoid many of the VKA drawbacks.7  In this review, we will focus 
on the current evidence justifying use of NOACs for stroke prevention in non-valvular AF. 
 
Decision making for stroke prevention versus bleeding, NOACs versus warfarin 
 
Oral anticoagulation therapy in AF patients always requires balancing the risk of stroke and 
other thromboembolic complications on the one hand and risk of bleeding (especially major 
bleeding), on the other. Therefore precise estimation of stroke and bleeding risk is 
obligatory both before treatment initiation and during follow-up.1,2 The risk of stroke and 
thromboembolic complications in AF patients depends largely on combination of various 
risk factors, which have been incorporated into various stroke risk assessment tools.  
 
Many guidelines now recommend the CHA2DS2-VASc score
8 (Table 1), which is best in 
distinguishing patients with low risk (CHA2DS2-VASc score of 0 in males or 1 in females) who 
do not require any antithrombotic therapy given the negative net clinical benefit in such 
patients (i.e. reduction of stroke and systemic embolic events does not outweigh increase of 
bleeding events).9-11 For other AF patients with ≥1 additional stroke risk factors (i.e. 
CHA2DS2-VASc score ≥ 1 in males or ≥2 in females) the net clinical benefit from oral 
anticoagulation is positive, showing that significant reduction of stroke rate can be achieved 
 balanced against a small increase of bleeding events, however, this has not been tested in 
randomized controlled trials.9-11 
 
There are some differences between the European Society of Cardiology (ESC) and American 
College of Cardiology (ACC) /American Heart Association (AHA) /Heart Rhythm Society (HRS) 
guidelines for the management of AF. While ESC guidelines in AF patients with the CHA2DS2-
VASc = 1, oral anticoagulation should be considered, ACC/AHA/HRS guidelines allow the 
choice between no treatment, aspirin or oral anticoagulation.1,2 Despite that not one of 
these approaches have been tested in large randomized controlled trials, stroke rate can be 
as high as 1.1 per 100 person-years in this subset of patients.12 Given the overlapping of the 
CHA2DS2-VASc and CHADS2 scores because of incorporation of the common risk factors with 
the same weight of 1 into two scores, one patient with the CHA2DS2-VASc = 1 may also have 
CHADS2 = 1, for which estimated stroke rate is even higher.
13,14 Thus, some patients will be 
exposed to unnecessary risk of disabling or even fatal stroke that can otherwise be 
prevented with oral anticoagulation. 
 
Among bleeding risk scores, the HAS-BLED score15 (Table 1) is recommended to assess 
patients’ one-year risk of hemorrhage given its simplicity for use in everyday practice and 
high performance in different subsets of patients, and, particularly, its ability to predict 
intracranial hemorrhage (ICH) that is undoubtedly the most feared complication of oral 
anticoagulation therapy.16 
 
Despite a range of limitations, warfarin is highly effective for stroke prevention in AF, 
reducing stroke by 64 % (95% confidence interval [CI] 49-74), both in primary (2.7% annual 
 absolute risk reduction) and secondary (8.4% annual absolute risk reduction) settings, as 
well as reducing all-cause mortality by 26% (95% CI 3–43).17 Warfarin is also significantly 
more effective than antiplatelet therapy with either aspirin alone (relative risk [RR] 
reduction 38 %, 95% CI 18-52) or dual antiplatelet therapy of aspirin and clopidogrel (RR 
1.72, 95% CI 1.24-2.37 for antiplatelets versus warfarin) with only minor increase of ICH 
when compared against aspirin alone and no difference in rate of major bleeding when 
compared against dual antiplatelet therapy.18  
 
Warfarin is also the more versatile oral anticoagulant that can be used in multiple clinical 
settings, which were omitted in the clinical trials on NOACs (e.g. severe renal failure, acute 
coronary syndromes in AF patients, etc.) or were found to be unsuitable for anticoagulation 
with the NOACs (e.g. mechanical heart valves). Therefore, maintenance and further 
development of services for INR control to improve safety and efficacy of warfarin therapy is 
still warranted. Also, while use of the NOACs is prioritized over warfarin according to 
European guidelines, the American guidelines do not give preference to the NOACs over 
(well controlled) warfarin.1,2 
 
In ‘real world’ clinical practice, the efficacy and safety of warfarin may be lower19 as the 
limitations of warfarin therapy often result in its underuse and poor quality of 
anticoagulation control20,21 evaluated as TTR. The lowest rate of strokes, systemic embolism 
and bleeding events are observed in patients with high TTR (e.g. >70%) and, vice versa, 
warfarin therapy but with poor TTR eventually results in increased risk of complications, 
with the patient having worse outcomes than if left untreated.22,23 Common clinical risk 
factors can be related to TTR, as recently reported by Apostolakis et al.24 
  
Thus, ‘switching’ anticoagulation from warfarin to NOACs is likely to be beneficial in patients 
with poorly controlled warfarin, with low TTRs, particularly if this is evident from patients’ 
experience of being on warfarin. However, this hypothesis has not been tested in any 
controlled trial yet. It is also challenging how to choose appropriate anticoagulation 
option(s) in anticoagulation-naïve patients because variability of anticoagulant effect of 
warfarin confers increased risk of bleeding during initial time, hence, ‘trial’ period with 
warfarin should be avoided. The SAMe-TT2R2 score (Table 1) was introduced to answer if a 
patient is expected to do well on warfarin (i.e. to maintain good TTR, those with score of 0 
to 1) or not (those with score ≥2).25,26   Regardless of the choice of anticoagulation, 
adherence factors related to education, geographic and cultural factors, social diversity, 
economics, and transportation as well as access to medical care from qualified clinicians, 
medical comorbidities, genetic variation should be considered. 
 
The NOACs have specific single targets in coagulation cascade (Figure 1).27 Dabigatran 
inhibits the enzymatic activity of thrombin (both free and clot-bound thrombin) that affects 
thrombin functions: conversion of fibrinogen to fibrin and its stabilization; activation of 
coagulation factors V, VIII, XI, and XIII; activation of platelets, inhibition of fibrinolysis, 
proinflammatory changes.28 Rivaroxaban, apixaban, and edoxaban inhibit enzymatic activity 
of factor Xa (both free and within prothrombinase complex) that eventually leads to 
downstream blockade of prothrombin to thrombin conversion.27 
 
In summary, the direct, dose-related, reversible inhibition with the NOACs together with 
few drug and food interactions lead to stable, rapidly attainable anticoagulation effect with 
 no necessity for a long and complicated process of dose adjustment and regular INR 
monitoring (Table 2). Pharmacological properties of the NOACs in comparison to warfarin 
are summarized in Table 3. 
 
Randomized clinical trials with NOACs for stroke prevention in AF 
 
Four large phase III prospective randomized clinical trials, competing safety and efficacy of 
NOACs to warfarin, have been completed: RE-LY with dabigatran30,31, ROCKET AF with 
rivaroxaban32, ARISTOTLE with apixaban33, and ENGAGE AF – TIMI 48 with edoxaban34 
(Tables 4 and 5). 
 
Trials on the oral direct factor Xa inhibitors were double-blind32-34, whereas the trial with 
dabigatran was open label between dabigatran and warfarin arms, but double blind 
between 2 arms with different doses of dabigatran (150 mg bid versus 110 mg bid).30    
 
There has been much discussion of pros and cons of two designs in anticoagulation trials. 
Both of them have some strengths and weaknesses at different levels and to different 
degrees. Therefore, trial design should not be considered as the only or main factor 
influencing analysis and interpretation of trial findings.35,36   For example, prospective 
randomized controlled trials using double-blinding of investigators and patients with respect 
to the actual treatment allocation may well be the gold standard in trial methodology, but 
are also more complex, and highly motivated and/or compliant patients may be enrolled. 
On the contrary, open-label trials are relatively simpler and involve more representative of 
real clinical practice population and arguably are more generalizable. Even with open-label 
 design, trials are subjected to selection (and other) bias.34-36 Data from observational trials 
and real-world cohorts are also needed to enhance the evidence on ‘new’ treatment.  
 
There were more enrolled patients with prior history of stroke, TIA or systemic embolism 
(and, hence, higher stroke risk according to the CHADS2 score), and a lower mean TTR in the 
ROCKET AF (55%).30,32-34 Thus, even in the idealized settings of clinical trials, commencing 
and continuing warfarin can be challenging since INR remained in the suboptimal range in 
many patients treated with warfarin. 
 
Discontinuation rates were higher in both dabigatran arms in comparison to warfarin arm in 
the RE-LY trial, whereas it was broadly similar for factor Xa inhibitors and warfarin in all 
other trials, which was related to higher rate of gastrointestinal adverse reactions.30,32-34  
High discontinuation rate and poor medication adherence is frequently found with 
pharmacological therapy, particularly for chronic conditions. The problem is complex and 
multifactorial, but many factors related to low adherence are common for chronic diseases, 
including stroke prevention with oral anticoagulation in AF patients. Educational level, 
smoking, working status, disability, indication for thromboprophylaxis, prior warfarin 
therapy, lower cognitive function, low scores on the mental component of the SF-36 health 
survey and poor baseline health appeared to be independent predictors of non-adherence 
to warfarin.38 Overall, these factors can be extrapolated to non-adherence to the NOACs. It 
is not a rare case when no apparent reason for drug discontinuation can be given by a 
patient.39-40  
 
 Non-requirement for regular laboratory assessment and BID administration (for dabigatran 
and apixaban) were considered to be reasons of poorer compliance with the NOACs in 
comparison to warfarin. One missed dose of a NOAC with moderate half-life (approx. 10-12 
hours) might eventually lead to adverse outcomes with higher probability than one missed 
dose of warfarin given the shorter half-life of most NOACs. For a drug with an 11 hour half-
life, for example, missing one dose on a once-daily (qd) regime is pharmacokinetically 
similar to missing 3 doses on the twice-daily (bid) regime.41 
 
Overall, in the meta-analysis of randomized controlled trials, discontinuation rate with 
NOACs was found not to be statistically different in comparison to pharmacologically active 
comparators (e.g. warfarin or aspirin) in patients with AF. When causes of discontinuation 
were analyzed separately, no differences were observed with respect to discontinuation due 
to adverse events or consent withdrawals (rates of discontinuation for non-adherence were 
not reported).42  Indeed, discontinuation rate particularly due to non-adherence may be 
higher when outside of a trial setting. Therefore, patients’ education is of paramount 
importance.43-45 
 
All studies shared similar primary efficacy (stroke or systemic thromboembolism) and safety 
(major bleeding) end points apart from the ROCKET-AF trial, in which primary safety end 
point included major and clinically relevant non-major bleeding.30-34 With respect to the 
primary efficacy end point, all NOACs were shown to be at least non-inferior to warfarin 
(low dose dabigatran, rivaroxaban, and both doses of edoxaban) or even superior to 
warfarin (high dose dabigatran, apixaban).30-34 Treatment with dabigatran 150 mg bid 
resulted in a significantly lower rate of ischemic stroke and cardiovascular mortality.30,31 The 
 latter was lower with both edoxaban doses as well.34 Apixaban and low dose edoxaban were 
associated with reduced all-cause mortality; however, edoxaban 30 mg qd appeared to be 
less protective against ischemic stroke.33,34 
 
There was a non-significant trend towards higher rate of myocardial infarction with both 
doses of dabigatran.31 One explanation for this is that therapeutic concentration of 
dabigatran, which is protective in a chronic setting, was perhaps insufficient to inhibit 
increased amount of thrombin within ruptured/erosed coronary plaque.46 In contrast, 
warfarin leads to a decrease of several coagulation factors as well as factor Xa inhibitors that 
allow upstream inhibition of the coagulation cascade (one inhibited molecule of factor Xa 
prevents conversion of approximately 1000 molecules of prothrombin to thrombin). 
 
In terms of safety, both doses of edoxaban, low dose dabigatran and apixaban were 
significantly better than warfarin, while rivaroxaban and a high dose of dabigatran were 
non-inferior.30-34 All the NOAC trials found a lower rate of both hemorrhagic stroke and ICH 
with NOACs compared to warfarin.30-34 High dose dabigatran and edoxaban as well as 
rivaroxaban were associated with increased rate of gastrointestinal bleeding that was 
probably due to their metabolism via P-gp (permeability glycoprotein) efflux transporter, 
expressed in intestine and therefore resulting in locally higher concentrations of NOACs.30-
32,34 In terms of the mortality end point, both dose regimens of edoxaban and high dose 
dabigatran were associated with a lower rate of death from cardiovascular causes. Also, low 
dose edoxaban and apixaban were associated with lower rate of death from all causes when 
compared to warfarin.30,31,33,34 
 
 Data regarding NOACs efficacy and safety were pooled in several systematic reviews and 
meta-analyses (Table 6), results across all were consistent: NOACs were found to be 
superior to warfarin with respect to prevention of stroke and systemic embolism, 
hemorrhagic stroke, ICH, and all-cause mortality; non-inferior with respect to rate of 
ischemic stroke and myocardial infarction.47-50 There was a trend towards reduced risk of 
major bleeding.  As discussed above, anticoagulation with NOACs resulted in more episodes 
of gastrointestinal bleeding.47,50 
 
When efficacy and safety of the NOACs in comparison to warfarin were modeled in the large 
Danish ‘real world’ AF population, the net clinical benefit for all the NOACs (data on 
edoxaban were not included into this analysis) favored their use in all patients with the 
CHADS2 score ≥1 or CHA2DS2-VASc score ≥2 irrespective of bleeding risk, with the greatest 
seen in patients with higher stroke and bleeding risk.10 Within the post-marketing 
assessment of the efficacy and safety of NOACs, dabigatran and rivaroxaban were consistent 
with their pivotal trial results.51,52 
 
Once-daily versus twice-daily dosing for the NOACs 
 
There are concerns regarding safety and efficacy about whether once daily regime 
(rivaroxaban and edoxaban) is the same as twice daily regime (dabigatran and apixaban) 
since all the NOACs have broadly similar and overlapping half-life times. Typically, qd dosing 
results in a greater maximum plasma concentration (Cmax) and lower or similar minimum 
plasma concentration (Ctrough) in comparison to bid regime dosing with the same total daily 
dose.53 However, the pharmacological profile of the drug, taken alone, is not sufﬁcient to 
 make a decision on optimal dosing regime. Indeed, balancing efficacy and safety is far 
beyond Cmax-Ctrough interplay. Nevertheless, pharmacodynamics of the NOACs (i.e. extent of 
anticoagulation effect) largely depends on its pharmacokinetics with maximum effect at Cmax 
(which is also related to risk of bleeding) and minimum effect at Ctrough below which 
anticoagulant effect is not sufficient and therefore related to risk of thromboembolic 
complications. However, this assumption was found not to work with all the NOACs.53 
 
The qd dosing of rivaroxaban was discovered via pharmacokinetic modeling based on 
pharmacokinetic data from the two phase II venous thromboembolism trials. Cmax was 
approximately 20% higher and Ctrough was approximately 60% lower with qd dosing when 
compared with bid dosing; however, the 5th–95th percentile ranges for both parameters 
were overlapping. Thus, a bid dosing of rivaroxaban might not provide more stable drug 
levels in the blood and anticoagulation effect.54 Better patient adherence to oral 
anticoagulation with the qd regime was also considered.  
 
In a phase II trial and pharmacological modeling study with edoxaban lower bleeding rates 
were associated with qd dosing compared with bid dosing of the same total daily dose of 60 
mg. Signiﬁcant correlation was observed between bleeding rates and Ctrough but not Cmax and 
thus, a qd dosing regime was selected for the phase III ENGAGE AF - TIMI 48 trial.55,56  
 
In the meta-analysis of qd versus bid dosing, the latter was found to be beneficial for stroke 
and systemic embolism prevention with dabigatran 150 mg (HR 0.75, 95% CI 0.58–0.96) but 
not for apixaban versus qd common estimate (rivaroxaban 20(15) mg and edoxaban 60(30) 
mg) as well as for ICH prevention with bid common estimate versus rivaroxaban (HR 0.57, 
 95% CI 0.37–0.88) but not versus edoxaban. Thus, bid dosing has a somewhat better risk-
benefit profile, but that may not be the case for all the NOACs.57  
 
Monitoring of anticoagulant activity with the NOACs 
 
Unfortunately, the available routine anticoagulation assays only provide clinicians with a 
qualitative assessment of anticoagulant effect with NOACs (Table 3).58 In terms of 
monitoring for the NOACs, all have been approved for use in AF patients without necessity 
for regular laboratory testing assuming a stable anticoagulation effect. However, a recent 
analysis of dabigatran trough plasma concentrations in a subgroup of patients from the RE-
LY trial in relation to their outcomes triggered extensive discussion of the pros and cons of 
dose adjustment based on concentration monitoring. 59-61 
 
In the analysis by Reilly et al, concentration of dabigatran was found to be associated with 
age, kidney function, weight, and female gender.62 Over a five-fold difference of 
concentration was observed between the 10th and 90th percentiles with either dose of 
dabigatran. Also, a proportion of patients appeared to have very low (and, hence, decreased 
stroke protection) or very high (and, hence, increased bleeding risk) plasma level of 
dabigatran.62 Such a drug level variability translates into concentration-dependent increase 
of rate of bleeding events. Nonetheless, the rate of stroke and systemic embolism appeared 
to be less affected within therapeutic range.62 Thus, authors suggested that laboratory 
guided adjustment of dabigatran dose might result in further improvement of its safety and 
efficacy in AF in comparison to fixed doses, at least in selected patients at higher risk (e.g. 
elderly and/or those with renal dysfunction).62 
  
On the contrary, results of mathematical modeling attempted to test the utility of 
dabigatran dose adjustments via measuring its plasma level did not support this strategy, 
because the simulations did not seem to allow reliable prognosis for actual patients’ 
outcomes.63 The variability of dabigatran concentrations when considered together with the 
RE-LY trial results reflects its wide therapeutic range in which it remains effective and safe 
rather than carries an inevitable threat to AF patients. Also, assays for evaluation of 
dabigatran concentration are not available routinely, making this approach complicated for 
everyday clinical practice. Oral Factor Xa inhibitors may be less subject to concentration 
variability, as observed for dabigatran, due to their higher bioavailability in comparison to 
dabigatran and also lower dependence on renal clearance (Table 3). 
Thus, whether regular laboratory control and concentration-based dose adjustment of 
dabigatran (and other NOACs) will bring additional benefits in comparison to current fixed 
dose approach without monitoring requires further clarification in controlled trials.  
 
Consistency of the NOACs across patients’ subgroups 
 
Data on overall efficacy and safety of the NOACs obtained from landmark trials appeared to 
be consistent across patients’ subgroups (Table 7). There were no statistically significant 
interactions shown among subgroups based on age34,64-66, CHADS2 score
32,34,67,68, kidney 
function32,69,70, symptomatic heart failure32,34,71,72, prior stroke or TIA34,73-75, concomitant use 
of antiplatelet drugs32,76,77, and center average TTR34,78-80 with respect to the primary 
efficacy end point. Data on subgroups according to kidney function and antiplatelet therapy 
use for edoxaban are not available as yet. While there was no significant interaction 
 between VKA-naïve and VKA-experienced AF patients for dabigatran, rivaroxaban, and 
apixaban30,32,81,  edoxaban did significantly better in the subgroup of VKA-naïve patients.34 
 
There was also no interaction across a majority of specified subgroups with respect to major 
bleeding. Lower (but non-inferior) efficacy of either dose of dabigatran in patients aged ≥75 
years was found.64 However, dabigatran still had a favorable safety profile for ICH in elderly 
AF patients in comparison to warfarin (RR 0.37, 95% CI 0.21-0.64, and RR 0.42, 95% CI 0.25-
0.70 for dabigatran 110 mg bid and 150 mg bid, respectively).64 Age does not apply any 
particular limitations with respect to NOACs use, although age-related decline in renal 
function, risk of falls, anemia, and other multiple comorbidities should be considered.82 
 
In the meta-analysis of AF and non-AF randomized controlled trials, risk of major or clinically 
relevant non-major bleeding did not differ between elderly patients (≥75 years old) taking 
one of the NOACs and those on conventional therapy or taking active comparator (warfarin, 
aspirin, or enoxaparin). Among AF patients, risk of stroke or systemic embolism favored use 
of the NOACs in elderly patients (OR 0.65, 95% CI 0.45-0.87).83 In young patients, AF often 
represents primarily electrical disorder and in the absence of stroke risk factors usually no 
oral anticoagulation is required; however if this is not the case, the safety and efficacy of the 
NOACs is unlikely to be worse than in the RE-LY trial and ‘real-world’ data. Use of the NOACs 
in younger patients is feasible at least in respect to quality of life since they do not apply so 
many restrictions and limitations as warfarin does, therefore allowing enhanced lifestyle. 
 
 Also, apixaban appeared to be safer than warfarin irrespective of kidney function, but the 
largest reduction in bleeding complications was achieved in patients with estimated 
glomerular filtration rate below 50 mL/min.70  
 
There was no significant interaction between center average TTR and major bleeding when 
comparing 150 mg dabigatran and rivaroxaban with warfarin, although there was a 
tendency to less bleeding events at lower average center TTR; also, no significant 
interactions with center TTR were found for ICH with both dabigatran regimes and 
rivaroxaban.78,79  
 
All NOACs were found to have similar warfarin efficacy and safety if cardioversion of AF to 
sinus rhythm was necessary during study follow-up.84-86 Similar to warfarin, management 
during the pericardioversion period apply to the NOACs (i.e. therapeutic anticoagulation 3 
weeks before and 4 weeks after procedure). In general, transesophageal echocardiography 
is not compulsory prior to cardioversion if patient was appropriately anticoagulated, unless 
there are doubts about patient adherence to treatment, since no routine tests are available 
to screen patient compliance while preparing for procedure.1,2,7 
 
NOACs in patients presenting with acute coronary syndrome and or undergoing 
percutaneous intervention 
 
AF and coronary artery disease (CAD) frequently coexist. Approximately 30% of AF patients 
have CAD, and approximately 15% of the latter undergo stent implantation.87  
 Presence of vascular disease, particularly a complicated one (e.g. history of myocardial 
infarction, revascularization, etc.) confers additional risk of stroke in AF patients, and 
therefore has been incorporated into the CHA2DS2-VASc score.
8 
 
According to current recommendations in patients with AF and stable CAD, oral 
anticoagulation either with the NOACs or dose-adjusted VKA is sufficient alone.88 No 
antiplatelets are required in addition to oral anticoagulation since in non-acute setting there 
is no significant reduction in the risk of coronary events or stroke and systemic embolism, 
whereas risk of bleeding is increased significantly (HR 1.50, 95% CI 1.23-1.82 with aspirin 
and HR 1.84, 95% CI 1.11-3.06 with clopidogrel).89  On the contrary, in patients with acute 
coronary syndrome (ACS) and/or undergoing percutaneous intervention (PCI) and stenting, 
combination of oral anticoagulation and antiplatelet therapy is needed to protect from both 
stroke and systemic embolism, and stent thrombosis since both pathways are activated (i.e. 
coagulation and platelet activation).90,91  
 
The choice and duration of the use of combination treatment depends on the clinical setting 
of coronary intervention (elective PCI stable CAD or primary one in ACS) and baseline stroke 
and bleeding risk.88  While previously bare metal stents (BMS) were recommended in order 
to reduce duration of triple therapy in comparison to (old generation) drug eluting stents 
(DES)92, new generation DES do not have any particular disadvantages to BMS with respect 
to major adverse events including composite of cardiac death, definite or probable stent 
thrombosis, myocardial infarction, or target-lesion revascularisation.88,93,94 
 
 In terms of NOACs use in this group of patients, the data are limited since patients after ACS, 
myocardial infarction or receiving dual-antiplatelet therapy were excluded from the AF trials 
and vice versa patients with AF were excluded from the ACS trials.  As discussed above, no 
difference with respect to the NOACs efficacy was observed between patients who did take 
antiplatelets during trial period concomitantly with oral anticoagulant and those who did 
not as well as there was broadly similar increase of major bleedings when combination of 
oral anticoagulation and antiplatelet drugs was used.32,34,76,77 
 
Several ACS trials (AF patients were excluded) with the NOACs were performed. Two 
regimes of rivaroxaban were studied in the phase III ATLAS ACS 2–TIMI 51 trial (2.5 mg bid 
and 5 mg bid) which were found to have the most favorable efficacy/safety profile in the 
phase II ATLAS ACS–TIMI 46 trial.95,96 Rivaroxaban significantly reduced the primary efficacy 
end point (death from cardiovascular causes, myocardial infarction, or stroke), when added 
to standard dual antiplatelet therapy as compared with placebo, irrespectively of dose: HR 
0.84, 95% CI 0.72–0.97 for 2.5 mg BID regime and HR 0.85, 95% CI 0.73–0.98 for 5 mg bid 
regime.95 The lower dose of rivaroxaban was also associated with the reduction of mortality 
end points: HR 0.66, 95% CI 0.51–0.86 for c cardiovascular mortality and HR 0.68, 95% CI 
0.53–0.87 for all-cause mortality.95 Nonetheless, better efficacy of triple therapy was 
achieved at a cost of higher rate of major bleeding and ICH.95 
 
In the phase III APPRAISE-2 trial, apixaban 5 mg bid in addition to standard antiplatelet 
therapy was tested. Notwithstanding trend towards lower rate of ischemic events with the 
2.5 mg bid and 10 mg qd regimes in the phase II APPRAISE trial, particularly when apixaban 
was added to aspirin monotherapy; no reduction in recurrent ischemic events but significant 
 increase in bleeding events, including fatal bleedings and ICH was observed in the APPRAISE-
2 in comparison to placebo irrespectively of antiplatelet therapy (aspirin monotherapy or 
aspirin with clopidogrel).97,98 Similarly, dose-dependent increase of major bleeding or 
clinically relevant non-major bleeding with no significant impact on rate of ischemic events 
was observed in patients after myocardial infarction in the phase II RE-DEEM trial with 
dabigatran.99 
 
Thus, in patients with a recent ACS, addition of one of the NOACs to antiplatelet therapy 
results in a modest reduction in cardiovascular events but a substantial increase in bleeding, 
most pronounced when NOACs are combined with dual antiplatelet therapy.100  Because 
rivaroxaban dose regimes were different from those in AF trials and since AF patients were 
excluded, the data from ACS trials cannot be directly extrapolated to AF patients who 
develop ACS and/or undergo stenting. 
 
In summary, oral anticoagulation has to be continued if it was indicated for stroke 
prevention in AF when AF precedes development of ACS. Also, there is no reason to make 
changes of an already established anticoagulation regime either with one of the NOACs or 
well-adjusted VKAs in each individual patient in acute setting. In ACS-first patients who 
develop new onset AF while taking dual antiplatelet therapy, oral anticoagulation should be 
initiated. In the absence of randomized trials, no preference is given to any of available 
anticoagulants.88 Given limited data on safety and efficacy of the NOACs as part of 
combination therapy with antiplatelet drugs in the setting of ACS and/or stenting as 
discussed above, several trials have been designed to address these patients. 
 
 Periprocedural management of the NOACs 
 
Oral anticoagulation in patients with AF and ≥1 stroke risk factor is life-long. Not 
infrequently the need for elective or urgent surgery may occur in anticoagulated patients. 
The latter poses them at higher risk of periprocedural bleeding complications and requires 
temporary interruption of treatment that in turn is associated with higher risk of stroke and 
thromboembolic events. The risk of periprocedural major bleeding varies depending on 
severity of tissue trauma during intervention.    
 
This aspect has been further addressed in the “European Heart Rhythm Association Practical 
Guide on the use of new oral anticoagulants”7 and 9th ACCP antithrombotic therapy 
consensus101, and three major bleeding risk categories of procedures (minimal, minor, and 
major procedures) were established.102  Minimal procedures are those with little tissue 
trauma (superficial skin and oral mucosal surgery, including skin biopsies, wound revisions, 
non-extraction dental treatment).102 Minor procedures were procedures with little tissue 
trauma, but relevant bleeding risk: transluminal interventions, pacemaker-related surgery, 
pleural and peritoneal puncture, eye surgery, endoscopy, laparoscopy, organ biopsies, 
dental extraction, hernia repair, and intramuscular and paravertebral injections.102 Major 
procedures include surgery associated with significant tissue trauma and high bleeding risk: 
open pelvic, abdominal and thoracic surgery, brain, vascular, orthopedic and trauma 
surgery.102 
 
Minimal procedures can be performed at Ctrough of the NOAC, i.e. 12-24 hours after the last 
intake for bid and qd dosing, respectively.7 In case of minor or major procedures, last dose 
 of the NOAC has to be taken 24 and 48 hours before intervention, respectively.7 Pre-
intervention termination of the NOAC should to be adjusted (extended) in patients with 
kidney dysfunction. Specific NOAC-free intervals have been suggested for each particular 
drug and degree of renal impairment.7 In case of emergent surgery in patients 
anticoagulated with the NOACs, it is recommended to postpone surgery as long as possible - 
at least 12 hours but ideally 24 hours after the last dose.7  Oral anticoagulation can be 
restarted 6-8 hours after procedure with immediate and complete hemostasis. For 
procedures associated with immobilization, reduced DVT prevention dose or intermediate 
dose of low molecular weight heparin can be used from 6–8 to 48-72 hours after surgery, 
and the NOAC restarted following heparin.7 
 
In the Dresden registry (2179 patients of which 595 (27.3%) underwent 863 procedures), the 
vast majority of procedures were classified as minor (74.3%) following by minimal (15.6%) 
and major (10.1%) procedures. Median duration of interruption of anticoagulation was 2 
(interquartile range [IQR] 2) days before and 1 (IQR 3) day after the procedure, resulting in a 
total duration of NOAC interruption of 3 (IQR 6) days.102 
 
Given the predictable pharmacokinetics/pharmacodynamics of the NOACs shorter 
interruption period and no bridging with heparin is required in comparison to warfarin. 
However, recent data indicate low adherence to this recommendation. As many as 30% of 
all procedures were performed with heparin bridging, which resulted in 5-fold higher risk of 
major bleedings.102 
 
 In the pivotal trials with the NOACs oral anticoagulation was interrupted in 25% of patients 
in the RE-LY trial for a surgical or invasive procedure103, in 33% of patients in the ROCKET AF 
trial for various reasons104, and in 34% of patients in the ARISTOTLE trial for invasive 
procedures.105  Overall, no difference in thrombotic events rate was observed between the 
NOAC and warfarin arms: both doses of dabigatran (0.50% versus 0.50%), rivaroxaban and 
(0.30% versus 0.41%), and apixaban (0.43% versus 0.56%).103-105 There was no difference in 
rate of major bleeding as well: 3.8% and 4.1% versus 5.6% for low and high dose of 
dabigatran versus warfarin; 0.99% versus 0.79% for rivaroxaban versus warfarin, and 1.55% 
versus 1.80% for apixaban versus warfarin.103-105 In the Dresden registry ,irrespectively of 
the NOAC used major cardiovascular events developed in 1.0% of patients, and major 
bleedings occurred in 1.2% of patients.102 
 
Standard hemostatic measures (compression, surgical hemostasis, fluid replacement) are 
sufficient to cure non-life-threatening bleeding; however, in life-threatening bleeding 
reversal agents (activated and non-activated prothrombin complex concentrate and 
recombinant factor VIIa) can be used (Table 3).7,106,107  In patients with dabigatran-related 
bleeding, hemodialysis is also a useful option because of low protein binding and high water 
solubility of dabigatran.108-110 
 
Continuation of the NOACs after thromboembolic and bleeding complications 
 
Similar to patients with stable therapeutic INR taking warfarin111, notwithstanding stable 
anticoagulation effect with the fixed doses of the NOACs, there is still a minor probability of 
the development of ischemic stroke and other thromboembolic complications, particularly 
 in patients with high estimated stroke risk according to the CHA2DS2-VASc score. Given the 
history of stroke, TIA or systemic embolism even without other risk factors assigns patient 
into high risk stratum of stroke recurrence, apparently oral anticoagulation should be 
continued as soon as disease course gets stable.  
 
However, some questions arise. Why did stroke (systemic embolism) develop despite 
appropriate anticoagulation? Taking into account the absence of routinely available 
laboratory assays to measure achieved degree of anticoagulation with the NOACs, our 
knowledge of anticoagulation efficacy in each individual case is based on the assumption 
that the patient takes the drug regularly. Thus, much attention has to be paid to ensure 
patient’s compliance. Educational programs are of paramount importance to increase 
patient adherence to treatment.43-45  
 
Also, other thromboembolism risk factors have to be checked and modified if possible 
(obviously, as part of primary rather than secondary prevention). For example, obesity is an 
independent risk factor of stroke development both in patients without AF and in those with 
arrhythmia.112,113   Indeed, overweight and obesity are associated with a 31% and 36% 
higher risk of ischemic stroke, thromboembolism, or death adjusted for the CHA2DS2-VASc 
score , respectively, among participants of the prospective Danish Diet, Cancer and Health 
study.113 Heavy smoking was found to confer significantly increased risk independent of the 
CHA2DS2-VASc score risk of thromboembolism or death with hazard ratios of 3.64 and 2.17 
for females and males respectively.114 Similarly, excess alcohol intake (>27 drinks per week 
for males and >20 drinks per week for females versus <14 drinks per week) resulted in 33% 
and 23% higher risk of thromboembolism or death.115 
 While patient compliance has been ascertained, the patient might be screened for 
hereditary and acquired hemostatic thrombophylic disorders, e.g. factor V Leiden, 
prothrombin G20210A variant, protein C, S, antithrombin III deficiency, dysfibrinogenaemia, 
antiphospholipid syndrome, malignancy, myeloproliferative disorders, estrogen 
replacement therapy, in which the NOACs were not tested and might not provide sufficient 
anticoagulation effect with dosages recommended for stroke prevention in non-valvular 
AF.7,116 Nonetheless, it is unknown whether routine screening for thrombophilic states in 
patients with ischemic stroke or TIA is useful and therefore it is not recommended to be 
performed on a routine basis.117  
 
The selection of an antithrombotic agent should be individualized on the basis of risk 
factors, cost, tolerability, patient preference, potential for drug interactions, and other 
clinical characteristics, including renal function and time in INR therapeutic range if the 
patient has been taking VKA therapy.117   The NOACs might be beneficial in patients who had 
history of poorly controlled INR (i.e. low TTR). Among the NOACs, factor Xa inhibitors can be 
switched to dabigatran that was found to be superior to warfarin for ischemic stroke 
prevention while factor Xa inhibitors were only non-inferior to warfarin. Vice versa, direct 
thrombin inhibitor dabigatran can be switched to rivaroxaban, apixaban or edoxaban if 
there are concerns about decreased dabigatran bioavailability and hence low trough plasma 
concentration (or pharmacogenetic variant associated with lower dabigatran bioavailability) 
because factor Xa inhibitors are all characterized with a higher bioavailability and therefore 
are likely to be less subjected to plasma concentration drop.118,119 
 
 When to reinitiate oral anticoagulation? Continuation of oral anticoagulation including the 
NOACs after ischemic stroke is recommended within 14 days after the onset of neurological 
symptoms.117 However if the risk of hemorrhagic conversion is high, which is dependent on 
the infarct size, quality of hypertension control, or there is evidence of hemorrhagic 
transformation on initial imaging, resumption of anticoagulation should be extended 
beyond this time threshold.117 One approach is based on the 1-3-6-12 day rule that means 
resumption of anticoagulation after 1 day in patients with TIA; after 3 days in patients with 
small, non-disabling infarct; after 6 days in patients with a moderate size stroke; and after 
12 days (2-3 weeks) in patients with large strokes.7 
 
The decision on oral anticoagulation in patients who developed ICH is even more 
challenging. According to the current labeling, recent ICH is a contraindication for the oral 
anticoagulants either with the NOACs or VKAs. The risk of ICH recurrence and stroke 
development related to anticoagulation resumption or withholding should be balanced 
based on individual characteristics.120  
 
In the BRAIN study (67% of patients with AF), warfarin reinitiation during the hospital stay 
(median 19.7 days) did not lead to higher bleeding and mortality rate.121 The rate of 
thrombotic complications did not differ between groups as well. The factors related to 
decision to resume anticoagulation were lower stroke severity and presence of prosthetic 
heart valves.121 On the contrary, the study of Majeed et al. showed higher rebleeding rate or 
expansion of ICH (14% versus 8%) but lower rate of thrombotic complications (2% versus 
18%) in patients who continued to take warfarin (median time from ICH development 5.6 
weeks, 56% of patients in study were those with AF).122 Importantly, therapeutic INR and 
 high TTR do not guarantee event-free survival if anticoagulation was resumed.121,122,123   The 
most important risk factor, affecting probability of ICH recurrence and hence safety of 
anticoagulation resumption, is its location. Patients with lobar location of ICH have a higher 
risk of rebleeding compared to those with deep hemispheric bleeding (e.g., basal ganglia, 
thalamus, or brainstem).124-126 The rate of ICH recurrence after lobar ICH varied substantially 
between studies from 4.4% to 22%; however it was higher than recurrence rate after deep 
hemispheric bleeding (2.1-4%) across all studies.124-126  It was suggested that baseline stroke 
risk should correspond to stroke rate of 6.5% or more (i.e. CHA2DS2-VASc score of 5 or 
higher) and risk of ICH recurrence should correspond to ICH rate less than 1.4% to trade off 
benefits and hazards of anticoagulation.124  
 
Robust evidence to provide guidance in this clinical setting is sparse.127,128 RCTs have not 
been performed to address this treatment dilemma. In the absence of randomized trials, 
there are no firm recommendations as well. Anticoagulation after non-lobar ICH 
(antiplatelet therapy after all ICH) might be considered while avoidance of long-term 
anticoagulation is probably recommended after spontaneous lobar ICH in patients with non-
valvular AF.127,128  Other markers have been suggested, like cerebral microbleeds on MRI 
and apolipoprotein E gene polymorphism; however their utilization for decision making has 
not been tested as well.129,130 
 
All the NOACs were found to cause significantly less ICH than well controlled warfarin.30-34 
Thus, in patients, which are eligible for resumption of anticoagulation because of high stroke 
risk, the NOACs might be a reasonable alternative to warfarin despite no studies that 
specifically addressed this subset of patients. 
  
In terms of other common bleeding locations, e.g. gastrointestinal bleeding, oral 
anticoagulation can be safely continued; however, no guidance when to resume therapy has 
been provided as well.131   Indeed, Qureshi et al. reported that restarting warfarin after 7 
days of bleeding was more favorable than after 1 month since it was associated with 
decreased thromboembolism (HR 0.71, 95% CI 0.54-0.93) and reduced mortality (HR 0.67, 
95% CI 0.56-0.81) but not recurrent gastrointestinal bleeding (HR 1.18, 95% CI 0.94-1.10).132 
These results appeared to be consistent with earlier data.133  
 
Careful evaluation of the cause of bleeding is of particular importance. For example, 
gastrointestinal bleeding may unmask pre-existing gastrointestinal tumors, which otherwise 
(without anticoagulation therapy) would be asymptomatic for a long time.134 Available data 
came from the warfarin studies. Given the higher risk of gastrointestinal bleeding with the 
NOACs than with warfarin, similar time frame (i.e. 7 days) should not be extrapolated 
directly to patients taking one of the NOACs.  
 
Tailoring anticoagulation to the patient using NOACs 
 
The NOACs changed the landscape of stroke prevention in AF patients. However, all NOACs 
are not the same as well as landmark trials on NOACs were not homogeneous (particularly, 
ROCKET AF), and meta-analyses underscoring their favorable efficacy and safety profile do 
not supply clinicians with an algorithm as to which NOAC to choose in a particular clinical 
situation.  
 
 How does one NOAC agent compare against another? This can only be answered with a 
head to head trial, but such a trial would be huge and expensive, and unlikely to be 
performed. As an alternative, indirect comparisons have been performed, using warfarin as 
a common denominator, notwithstanding the various limitations of such methodology. 135  
 
No significant differences in efficacy end points including mortality were noted between 
apixaban and dabigatran (both dosages) or rivaroxaban.49 Dabigatran 150 mg bid was 
associated with lower risk of stroke and systemic embolism (HR 0.74, 95% CI 0.56–0.97), 
hemorrhagic stroke (HR 0.44, 95% CI 0.20–0.96) and non-disabling stroke (HR 0.60, 95% CI 
0.37–0.97) compared to rivaroxaban. 49 Apixaban was associated with less major bleeding 
compared with dabigatran 150 mg bid (HR 0.74, 95% CI 0.61–0.91) and rivaroxaban (HR 
0.66, 95% (0.54–0.81), but not significantly different from dabigatran 110 mg bid which was 
also safer than rivaroxaban (HR 0.77, 95% CI 0.63–0.94). 49 The results were consistent with 
one more indirect comparison of dabigatran, rivaroxaban and apixaban. 136   
 
Separate comparisons for primary and secondary stroke prevention were carried out by 
Rasmussen et al., who found apixaban to be superior to dabigatran 110 mg bid for certain 
types of stroke (HR 0.59, 95% CI 0.36-0.97), and to dabigatran 150 mg bid, resulting in less 
major (HR 0.75, 95% CI 0.60-0.94) and gastrointestinal (HR 0.61, 95% CI 0.42-0.89) bleeding, 
but less protective against any type of stroke (HR 1.45, 95% CI 1.01-2.08) when compared 
with the high dosage dabigatran. 137  For secondary prevention of stroke, no significant 
differences in safety and efficacy between dabigatran 150 mg, rivaroxaban, and apixaban 
were found apart from a less myocardial infarctions with apixaban in comparison to high 
dosage of dabigatran (HR 0.39, 95% CI 0.16-0.95) and less hemorrhagic stroke (HR 0.15, 95% 
 CI 0.03-0.66), vascular death (HR 0.64, 95% CI 0.42-0.99), major bleeding (HR 0.68, 95% CI 
0.47-0.99), and ICH (HR 0.27, 95% CI 0.10-0.73) with the low dosage of dabigatran versus 
rivaroxaban.137 
 
The most recent indirect comparisons also included data on edoxaban 30 mg qd and 60 mg 
qd.138,139 High dose edoxaban was found to be associated with higher rate of stroke and 
systemic embolism, stroke and hemorrhagic stroke in comparison to dabigatran 150 mg bid, 
and to cause less major bleeding than rivaroxaban, but more major or clinically relevant 
non-major bleeding and gastrointestinal bleeding than apixaban.138,139 Low dose edoxaban 
appeared to be less effective for stroke and systemic embolism, any stroke and ischemic 
stroke than all NOACs but dabigatran 110 mg bid.138,139 However, lower dose edoxaban was 
associated with significantly reduced rate of major bleeding (compared to all NOACs) and 
gastrointestinal bleeding (compared to all NOACs but apixaban).138,139 Either dose regime of 
edoxaban did not differ from other NOACs with respect to ICH and mortality end 
points.138,139 
 
Given the available data on NOACs, anticoagulation regimen in patients with non-valvular 
AF can be tailored to each individual case, considering the risks and the benefits, side 
effects, comorbidities, and patients’ preferences. Thus, we can fit the drug to the patient 
(and vice versa). For example, high dose dabigatran, given its superiority over warfarin for 
ischemic stroke prevention, might be considered in patients with the high CHA2DS2-VASc 
score, but if patients also have a high bleeding risk (e.g. HAS-BLED ≥3), apixaban, dabigatran 
110 mg bid or edoxaban is preferred. Dabigatran is associated with gastrointestinal side 
effects; hence, oral factor Xa inhibitors might be used instead in patients with dyspepsia. 
 Low dose dabigatran or edoxaban and dose adjustment of apixaban and edoxaban should 
be considered in patients with kidney diseases, depending on their renal function. Where 
patients may prefer a once daily regimen of anticoagulation, thus, rivaroxaban and 
edoxaban allow this. 
 
Future directions 
Ongoing clinical trials 
A large body of evidence supporting safety and efficacy of the NOACs for stroke prevention 
in AF is already available, but many questions in terms of use of NOACs in specific clinical 
settings (cardioversion and ablation of AF, concomitant use with antiplatelet drugs in 
patients with coronary artery disease undergoing stenting, severe kidney dysfunction, etc.) 
remain unanswered because of limited evidence from post-hoc or prespecified analysis of 
subgroups or exclusion from the landmark trials. 
 
Many clinical trials have been initiated to overcome these gaps in data. Cardioversion of AF 
to sinus rhythm is associated with an increased risk of thromboembolic complications, and 
therefore even low risk patients require pericardioversion anticoagulation. Safety and 
efficacy of the NOACs for this purpose is studied in X-VERT and ARC trials with 
rivaroxaban140,141, EMANATE with apixaban142, and ENSURE-AF with edoxaban143.  
 
Ablation of AF is increasingly used in arrhythmia management. Apart from patient’s 
background stroke risk, it is associated with additional risk of thrombogenesis due to 
presence of foreign bodies in the circulation and occurrence of areas of stasis produced by 
them; denaturation of blood proteins; endothelial damage; atrial stunning caused by 
 ablation, etc. Oral anticoagulation using dabigatran (DAPPAR AF144, ODIn-AF145, and one trial 
from Vanderbilt University146) and rivaroxaban (VENTURE-AF75147, OCEAN148) are being 
evaluated in patients that undergo AF ablation therapy. Because left atrial appendage (LAA) 
is considered to be the main source of thrombi in AF, efforts were directed towards 
determining the effect of the NOACs on LAA thrombus resolution, for example, in the  X-TRA 
trial with rivaroxaban.149 
 
To study whether the NOACs have the same efficacy and safety as warfarin conventionally 
used as part of triple therapy in patients with AF undergoing PCI, is the purpose of the 
REDUAL-PCI trial with dabigatran150, and PIONEER AF-PCI151 and REWRAPS152 with 
rivaroxaban.  It is also challenging when to restart oral anticoagulation in patients following 
acute ischemic stroke because of increased risk of stroke recurrence as well as ICH. The 
RELAXED153 and TripleAXEL154 studies have been designed to assess safety and efficacy of 
rivaroxaban in AF patients with acute ischemic stroke.  While dabigatran 75 mg bid received 
FDA approval in severe kidney dysfunction (CrCl 15-30 mL/min), this was based on 
pharmacokinetic modeling and simulation. Thus, this regime is currently undergoing testing 
in a clinical trial.155 
 
Importantly, NOACs can be used in non-valvular AF, which is defined by European guidelines 
as AF in the absence of rheumatic valvular disease (predominantly mitral stenosis) or 
prosthetic heart valves.1 The American guidelines also include bioprosthetic heart valves 
and mitral valve repair, as ‘valvular AF’.2 Valvular AF was an exclusion criterion in the pivotal 
NOAC trials. Indeed, the RE-ALIGN trial of dabigatran in patients with heart valve 
replacement was terminated prematurely due to excess of thromboembolic and bleeding 
 events among patients in the dabigatran arm compared with warfarin.156 However, a new 
pilot trial with dabigatran has been initiated to study its safety and efficacy in patients with 
mitral and/or aortic bioprosthetic valves (DAWA study).157 
 
Antidote program 
One of the important limitations of the NOACs is absence of an antidote to reverse 
anticoagulation when necessary. Activated or non-activated prothrombin complex 
concentrates can be used instead. Nonetheless, specific antidotes have been developed and 
are currently being tested in clinical trials. 
 
Idarucizumab, a fully humanized antibody fragment (Fab) was developed as a specific 
antidote for dabigatran. 158 It is structurally similar to thrombin, but its affinity for 
dabigatran is approximately 350 times higher than for thrombin. Idarucizumab does not 
bind to known thrombin substrates, and does not affect coagulation or platelet aggregation 
assays. Idarucizumab can reverse dabigatran activity within one minute of intravenous 
injection. Patients with uncontrolled bleeding or requiring emergency surgery or procedures 
are treated with idarucizumab in an ongoing phase 3 clinical trial RE-VERSE AD (A Study of 
the RE-VERSal Effects of Idarucizumab on Active Dabigatran).159  
 
Andexanet α, modified recombinant factor Xa has been developed as an antidote for factor 
Xa inhibitors.160 Andexanet α acts as a factor Xa decoy catching circulating factor Xa 
inhibitor, hence, allowing intrinsic factor Xa to escape inhibition and take part in the 
coagulation cascade. Andexanet α is enzymatically inactive due to several modifications, in 
comparison to normal factor Xa, for example, being unable to cause prothrombin activation 
 and to bind to phospholipids in the prothrombinase complex. This agent works in a dose-
dependent manner, and several Phase 3 studies have been designed to study the ability of 
andexanet α to reverse anticoagulation effect of currently available oral factor Xa 
inhibitors.161,162 
 
Conclusion 
With the introduction of NOACs, the landscape of oral anticoagulation for stroke prevention 
in patients with non-valvular AF has undoubtedly changed. Given the availability of different 
agents, clinicians currently have a choice not only between VKAs and NOACs, but inside 
NOAC class as well, tailoring oral anticoagulation to the patient.  Further randomized clinical 
trials as well as ‘real world’ data will help with better understanding of NOACs’ pros and 
cons in AF. 
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 Table 2. Pros and cons of the NOACs 
Pros 
 
Cons 
Wide therapeutic window, predictable 
anticoagulation response with standard 
doses 
No specific antidote available 
No need for (frequent) monitoring and dose 
adjustment 
Missed dose can increase the risk of stroke 
Absence of food interactions (no dietary 
restrictions, enhanced lifestyle) 
No routine coagulation monitoring may 
facilitate non-compliance 
Limited drug interactions (simplifies therapy) No coagulation assay easily available to 
precisely measure anticoagulation effect* 
Rapid onset of action and relatively short 
half-life periods (convenient around 
procedures; no need for bridging)  
Not approved in valvular AF and end-stage 
kidney disease 
Targeted action - reduced risk of associated 
effects 
Higher cost for patients† 
 Long term adverse effects not fully known 
yet 
 
* Situations which may warrant precise measurement of anticoagulation effect with the 
NOACs include unexpected thrombotic or bleeding event during treatment, evaluation for 
urgent surgery, kidney failure with impaired drug clearance, suspected drug overdose, 
suspected noncompliance, uncertain GI absorption, risk factor profile (weight, advanced 
age) that could affect dosing, evaluation for tPA therapy for acute stroke. 
† Given the non-requirement for frequent laboratory control and dose-adjustment with the 
NOACs as well as their efficacy and safety profile, overall all of the NOACs are cost-effective 
in comparison to VKAs. 
 
  
 Table 3. Pharmacological characteristics of warfarin and non-VKA oral anticoagulants 7,29 
Parameter Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban 
Mechanism of 
action 
Inhibition of 
VKORC1 
Direct thrombin 
inhibitor (free 
or bound), 
reversible 
Factor Xa 
inhibitor 
(free or 
bound), 
reversible 
Factor Xa 
inhibitor 
(free or 
bound), 
reversible 
Factor Xa 
inhibitor 
(free or 
bound), 
reversible 
Onset of 
action 
Slow, indirect 
inhibition of 
clotting factor 
synthesis 
Fast Fast Fast Fast 
Offset of 
action 
Long Short Short Short Short 
Absorption Rapid Rapid, acid-
dependent 
Rapid Rapid Rapid 
Bioavailability, 
% 
>95 6.5 >80 >50 62 
Tmax, hour 2.0-4.0 1.0-3.0 2.5-4.0 1.0-3.0 1.0-2.0 
Vd, L 10 60-70 50-55 21 >300 
Protein 
binding, % 
99 35 95 87 40-59 
T1/2β, hour 40 12-17 9-13 8-15 9-11 
Renal 
excretion 
None 80 35 27 50 
Non-renal 
excretion 
None 20 65 73 50 
CL/F, L/hour 0.35 70-140 10 5 30.2-33.7 
Accumulation 
in plasma 
Dependent on 
CYP2C9 metabolic 
efficiency 
None None 1.3-1.9 Negligible 
Food effect No effect on 
absorption; dietary 
vitamin K influence 
on 
pharmacodynamics 
Delayed 
absorption with 
food with no 
influence on 
bioavailability 
Delayed 
absorption 
with food 
with 
increased 
bioavailability 
None None 
Age Yes, lower CL/F as 
age increases 
Yes, lower CL/F 
as age 
increases 
None Yes, lower 
CL/F as age 
increases 
NR 
Body weight Yes, higher dose 
for increased 
weight 
None None Yes, higher 
exposure 
with low 
body weight 
(< 60 kg) 
Yes, higher 
exposure 
with low 
body weight 
(< 60 kg) 
Sex Yes, lower CL/F in 
women 
Yes, lower CL/F 
in women 
None Yes, higher 
exposure in 
Minimal 
 women 
Ethnicity Lower dose in 
Asian patients; 
higher dose in 
African-American 
patients 
None Lower dose 
in Japanese 
patients 
None None 
Drug 
transporter 
None P-gp P-gp, BCRP P-gp, BCRP P-gp 
CYP-mediated 
metabolism 
CYP2C9, CYP3A4, 
CYP2C19, CYP1A2 
None CYP3A4/5, 
CYP2J2 
(equal) 
CYP3A4/5, 
CYP2J2 
(minor), 
CYP1A2 
(minor) 
CYP3A4 (4%) 
Drug-drug 
interactions* 
Numerous Potent P-gp 
inhibitors 
(verapamil, 
reduce dose; 
dronedarone: 
avoid) and 
inducers (avoid) 
Potent 
CYP3A4 and 
P-gp 
inhibitors 
(avoid) and 
inducers (use 
with caution) 
Potent 
CYP3A4 and 
P-gp 
inhibitors 
(avoid) and 
inducers (use 
with caution) 
Potent P-gp 
inhibitors 
(reduce 
dose) and 
inducers 
(avoid) 
Coagulation 
measurement 
INR TT, dTT, aPTT, 
ECA
PT, anti-FXa anti-FXa PT, aPTT, 
anti-FXa 
Reversal 
agents 
Vitamin K (slow 
reversal, prolonged 
inhibition), FFP or 
PCCs (rapid 
reversal) 
 
Activated 
charcoal or 
haemodialysis 
(overdose); 
PCCs or 
recombinant 
FVII 
(uncontrolled 
bleeding) 
Activated 
charcoal, FFP, 
PCCs, 
activated FVII 
 
Activated 
charcoal, 
FFP, PCCs, 
activated FVII 
Activated 
charcoal, 
FFP, PCCs, 
activated 
FVII 
Dosing for AF Individualised for 
each patient 
according to INR 
response (0.5-16 
mg qd) 
150 mg bid or 
110 mg bid in 
high bleeding 
risk 
Contraindicated 
if CrCl < 30 
mL/min† 
20 mg qd if 
CrCl > 50 
mL/min or 15 
mg qd if CrCl 
15-50 
mL/min 
5 mg bid or 
2.5 mg bid if  
 CrCl 
15-29 
mL/min or 
 any 2 
of the 
following are 
present: 
o age ≥ 
80 years 
o body 
weight ≤ 60 
kg 
o serum
creatinine ≥ 
Awaiting 
EMA and 
FDA 
approval‡ 
  
AF, atrial fibrillation; aPTT, activated partial thromboplastin test; BCRP, breast cancer 
resistance protein; bid, twice daily; CL/F, apparent clearance; CrCl, creatinine clearance; 
CYP, cytochrom P450 isozymes; dTT, diluted thrombin test; ECT, ecarin chromogenic assay; 
EMA, European Medicines Agency; F, factor; FFP, fresh frozen plasma; INR, international 
normalized ratio; NR, not reported; qd, once daily; PCC, prothrombin complex concentrate; 
P-gp, permeability glycoprotein; PT, prothrombin time; Tmax, time to maximum plasma 
concentration; TT, thrombin time; T1/2β, terminal half-life, Vd, volume of distribution; 
VKORC1, vitamin K epoxide reductase enzyme subunit 1. 
*Potent inhibitors of CYP3A4 include antifungals (e.g., ketoconazole, intraconazole, 
voriconazole, posaconazole), chloramphenicol, clarithromycin, and protease inhibitors (e.g., 
ritonavir, atanazavir). P-gp inhibitors include verapamil, amiodarone, quinidine, and 
clarithromycin. P-gp inducers include rifampicin, St. John’s wort (Hypericum perforatum), 
carbamazepine, and phenytoin. Potent CYP3A4 inducers include phenytoin, carbamazepine, 
phenobarbital, and St. John’s wort 
† FDA approved administration of dabigatran 75 mg bid to patients with CrCl 15-30 mL/min 
‡ in the ENGAGE AF-TIMI 48 two dosages were tested: 30 mg qd and 60 mg qd, reduced to 
15 mg qd and 30 mg qd, respectively, if any of the following were present: CrCl 30-50 
ml/min, body weight ≤60 kg, or concomitant use of verapamil or quinidine 
  
133 ϕmol/L 
 Table 4. Summary of pivotal clinical trials of non-VKA oral anticoagulants in patients with 
non-valvular AF 
Clinical trial RE-LY30,31 ROCKET AF32 ARISTOTLE33 ENGAGE AF - TIMI 4834 
Non-VKA OAC 
examined  
Dabigatran Rivaroxaban Apixaban Edoxaban 
Trial design PROBE Double-blind, 
double-
dummy 
Double-blind, 
double-dummy 
Double-blind, double-
dummy 
Patients  18113 14 264 18 201 21105 
Age, years  71 73 70 72 
Mean CHADS2 
score  
2.1 3.5 2.1 2.8 
Non-VKA OAC 
dosing arm  
110 mg bid 150 mg bid 20 (15) mg qd 5 (2.5) mg bid 30 (15) mg 
qd 
60 (30) mg 
qd  
Prior vitamin K 
antagonist 
treatment, %  
50 62 57 59.2 58.8 
Prior stroke or 
transient ischemic 
attack, %  
20 (including SE) 55 19 (including 
SE) 
28.5  28.1 
Mean TTR, warfarin 
arm; %  
64 55 62 68.4 
Discontinuation 
rate, % 
21.2 vs 
16.6 
20.7 vs 
16.6 
23.9 vs 22.4 25.3 vs 27.5 33.0 vs 
34.5 
34.4 vs 
34.5 
Hazard ratios (95% CI) for NOACs versus warfarin 
Stroke or systemic 
embolism 
0.90 (0.74-
1.10) 
0.65 (0.52-
0.81) 
0.88 (0.75-
1.03) 
0.79 (0.66-
0.96) 
1.13 (0.96-
1.34) 
0.87 (0.73-
1.04) 
Ischaemic stroke 1.11 (0.89-
1.40)* 
0.76 (0.60-
0.98)* 
0.94 (0.75-
1.17) 
0.92 (0.74-
1.13) § 
1.41 (1.19-
1.67) 
1.00 (0.83-
1.19) 
Haemorrhagic 
stroke 
0.31 (0.17-
0.56) 
0.26 (0.14-
0.49) 
0.59 (0.37, 
0.93) 
0.51 (0.35-
0.75) 
0.33 (0.22-
0.50) 
0.54 (0.38-
0.77) 
Systemic embolism 1.26 
(0.57—
2.78)† 
1.61 (0.76-
3.42)† 
0.23 (0.09, 
0.61) 
0.87 (0.44-
1.75) 
1.24 (0.72-
2.15) 
0.65 (0.34-
1.24) 
All-cause mortality 0.91 (0.80-
1.03) 
0.88 (0.77-
1.00) 
0.85 (0.70-
1.02) 
0.89 (0.80-
0.998) 
0.87 (0.79-
0.96) 
0.92 (0.83-
1.01) 
Cardiovascular 
mortality 
0.90 (0.77-
1.06) 
0.85 (0.72-
0.99) 
0.89 (0.73, 
1.10) 
0.89 (0.76-
1.04) 
0.85 (0.76-
0.96) 
0.86 (0.77-
0.97) 
Myocardial 
infarction  
1.29 (0.96-
1.75) 
1.27 (0.94-
1.71) 
0.81 (0.63-
1.06) 
0.88 (0.66-
1.17) 
1.19 (0.95-
1.49) 
0.94 (0.74-
1.19) 
Major bleeding  0.80(0.70-
0.93) 
0.93 (0.81-
1.07) 
1.04 (0.90-
1.20) 
0.69 (0.60-
0.80) 
0.47 (0.41-
0.55) 
0.80 (0.71-
0.91) 
Major or clinically 
relevant nonmajor 
NA NA 1.03 (0.96-
1.11) 
0.68 (0.61-
0.75) 
0.62 (0.57-
0.67) 
0.86 (0.80-
0.92) 
 bleeding 
Intracranial 
hemorrhage  
0.30 (0.19-
0.45) 
0.41 (0.28-
0.60) 
0.67 (0.47-
0.93) 
0.42 (0.30-
0.58) 
0.30 (0.21-
0.43) 
0.47 (0.34-
0.63) 
Gastrointestinal 
bleeding 
1.09 (0.85-
1.39) 
1.49 (1.19-
1.88) 
1.47 (1.20-
1.81) 
0.88 (0.67-
1.14) 
0.67 (0.53-
0.83)  
1.23 (1.02-
1.50) 
Any bleeding 0.78 (0.74-
0.83) 
0.91 
(0.86-
0.97) 
NA 0.71 (0.68-
0.75) 
0.66 (0.62-
0.71) 
0.87 (0.82-
0.92) 
 
ARISTOTLE, Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial 
fibrillation; bid, twice daily; CHADS2, congestive heart failure, hypertension, age >75 years, 
diabetes mellitus, stroke or transient ischemic attack (2 points); CI, confidence interval; 
ENGAGE AF – TIMI 48 Effective aNticoaGulation with factor Xa next GEneration in Atrial 
Fibrillation – Thrombolysis In Myocardial Infarction 48; NA, data not available; OAC, oral 
anticoagulant; qd, once daily; PROBE, prospective, randomized, open-label, blinded end 
point; RE-LY, Randomized Evaluation of Long-term anticoagulation therapy; ROCKET AF, 
Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism 
for prevention of stroke and Embolism Trial in Atrial Fibrillation; SE, systemic embolism; TTR, 
time in therapeutic range. 
* ischaemic or uncertain  
† pulmonary embolism 
  
 Table 5. Summary of outcomes in pivotal trials on efficacy and safety of NOACs versus 
warfarin in patients with non-valvular AF 
Outcomes Dabigatran 
110 mg 
bid30,31 
Dabigatran 
150 mg 
bid30,31 
Rivaroxaban 
20 (15) mg 
qd32 
Apixaban 
5 (2.5) mg 
bid33 
Edoxaban 
30 (15) 
mg qd34 
Edoxaban 
60 (30) 
mg qd34 
Stroke/systemic 
embolism 
↔ ↓ ← ↓ → ← 
Ischaemic 
stroke 
↔* ↓* ↔ ↔* ↑ ↔ 
Haemorrhagic 
stroke 
↓ ↓ ↓ ↓ ↓ ↓ 
Systemic 
embolism 
↔† ↔† ↓ ↔ ↔ ↔ 
All-cause 
mortality 
↔ ← ← ↓ ↓ ← 
Cardiovascular 
mortality 
↔ ↓ ↔ ← ↓ ↓ 
Myocardial 
infarction 
→ → ↔ ↔ ↔ ↔ 
Major bleeding ↓ ↔ ↔ ↓ ↓ ↓ 
Major or 
clinically 
relevant non-
major bleeding 
NA NA ↔ ↓ ↓ ↓ 
Intracranial 
bleeding 
↓ ↓ ↓ ↓ ↓ ↓ 
Gastrointestinal 
bleeding 
↔ ↑ ↑ ↔ ↓ ↑ 
Any bleeding ↓ ↓ NA ↓ ↓ ↓ 
 
* ischaemic or uncertain  
† pulmonary embolism 
↑, significantly increased; ↓, significantly decreased; →, trend toward increased; ←, trend 
towards decreased; ↔, neither significant difference nor trend were observed 
NA, data not available; qd, once daily 
 Table 6. Systematic reviews and meta-analyses on efficacy and safety of NOACs 
 
* additional 3 trials on NOACs in VTE included for analysis of bleeding events 
† phase II and phase III  trials were included 
‡ analysis with data from low and high dosages of dabigatran arms being included 
separately (dabigatran 110 mg bid + other NOACs / dabigatran 150 mg bid + other NOACs) 
GI, gastrointestinal; ICH, intracranial haemorrhage; NA, data not available; SE, systemic 
embolism 
  
Revie
w 
NOACs N of 
include
d 
studies 
Efficacy and safety end points, HR (95% CI) for NOACs versus 
warfarin 
Stroke/S
E 
Ischemi
c 
stroke 
Hemorrhag
ic stroke 
All-
cause 
death 
Myocardi
al 
infarction 
Major 
bleedin
g 
ICH GI 
bleedin
g 
Adam 
et 
al.47 
Dabigatra
n 
Rivaroxab
an 
Apixaban 
3* NA 0.89 
(0.78-
1.02) 
0.48 (0.36-
0.62) 
0.88 
(0.82-
0.96) 
NA 0.80 
(0.63-
1.01) 
NA 1.3 
(0.97-
1.73) 
Denta
li et 
al.48  
Dabigatra
n 
Rivaroxab
an 
Apixaban 
Edoxaban 
12† 0.77 
(0.70-
0.86) 
0.92 
(0.81-
1.04) 
NA 0.89 
(0.83-
0.96) 
0.99 
(0.85-
1.15) 
0.86 
(0.80-
0.93) 
0.46 
(0.39
-
0.56) 
NA 
Lip et 
al.49  
Dabigatra
n‡ 
Rivaroxab
an 
Apixaban 
3 0.86 
(0.77-
0.95) / 
0.79 
(0.71-
0.88) 
0.98 
(0.87-
1.12) / 
0.88 
(0.77-
1.00) 
0.49 (0.37-
0.63) / 
0.47 (0.36-
0.62) 
0.89 
(0.83
—
0.96) 
/ 0.88 
(0.82-
0.95) 
0.95 
(0.81-
1.12) / 
0.95 
(0.81-
1.12) 
0.83 
(0.77-
0.90) / 
0.88 
(0.81-
0.95) 
0.47 
(0.38
-
0.57) 
/ 
0.49 
(0.40
-
0.60) 
NA 
Ruff 
et 
al.50 
Dabigatra
n 
Rivaroxab
an 
Apixaban 
Edoxaban 
4 0.81 
(0.73–
0.91) 
0.92 
(0.83–
1.02) 
0.49 (0.38–
0.64) 
0.90 
(0.85–
0.95) 
0.97 
(0.78–
1.20) 
0.86 
(0.73–
1.00) 
0.48 
(0·39
–
0.59) 
1.25 
(1.01–
1.55) 
 Table 7. Consistency of results on the efficacy and safety of NOACs across patient 
subgroups 
Subgroups Outcom
es 
Stroke and systemic embolism 
HR (95% CI) for NOACs versus 
warfarin 
Major bleeding 
HR (95% CI) for NOACs versus 
warfarin 
Drug, 
dose* 
Dabigat
ran 110 
mg bid  
Dabigat
ran 150 
mg bid 
Rivaroxa
ban 20 
(15) mg 
Apixab
an 5 
(2.5) 
mg 
Dabigat
ran 110 
mg bid  
Dabigat
ran 150 
mg bid 
Rivaroxa
ban 20 
(15) mg† 
Apixab
an 5 
(2.5) 
mg 
Age64-66 <75 0.93 
(0.70–
1.22) 
0.63 
(0.46–
0.86) 
0.95 
(0.76-
1.19) 
1.16 
(0.77-
1.73) / 
0.72 
(0.54-
0.96) ‡ 
0.62 
(0.50–
0.77) 
0.70 
(0.57–
0.86) 
0.96 
(0.78-
1.19) 
0.78 
(0.55-
1.11) / 
0.71 
(0.56-
0.89)† 
≥75 0.88 
(0.66–
1.17) 
0.67 
(0.49–
0.90) 
0.80 
(0.63-
1.02) 
0.71 
(0.53-
0.95) 
1.01 
(0.83–
1.23) § 
1.18 
(0.98–
1.42) § 
1.11 
(0.92-
1.34) 
0.64 
(0.52-
0.79) 
Stroke risk 
(CHADS2 
score)32,67,68 
0-1 0.98 
(0.63-
1.51) 
0.61 
(0.37-
0.99) 
NA 0.85 
(0.57–
1.27) 
0.65 
(0.49 to 
0.88) 
0.74 
(0.56 to 
0.99) 
NA 0.59 
(0.44–
0.78) 
2 1.06 
(0.74-
1.52) 
0.61 
(0.40-
0.92) 
0.85 
(0.52—
1.38) 
0.90 
(0.66–
1.23) 
0.90 
(0.71 to 
1.14) 
0.92 
(0.72 to 
1.17) 
0.92 
(0.51-
1.66) 
0.76 
(0.60–
0.96) 
3-6 0.78 
(0.58-
1.04) 
0.69 
(0.51-
0.93) 
0.76 
(0.57-
1.01) / 
0.95 
(0.72—
1.24) / 
0.88 
(0.58-
1.34) / 
1.49 
(0.62-
3.59) ¶ 
0.70 
(0.54–
0.91) 
0.83 
(0.66 to 
1.03) 
1.07 
(0.87 to 
1.31) 
0.67 
(0.48-
0.93) / 
0.78 
(0.57-
1.07) / 
0.95 
(0.59-
1.51) / 
1.0 
(0.35-
2.88) § 
0.70 
(0.56–
0.88) 
Kidney 
function  (CrCl, 
mL/min)32,69,70 
>80 0.84 
(0.54–
1.32) 
0.67 
(0.42–
1.09) 
0.94 
(0.67-
1.31) 
0.88 
(0.64-
1.22) 
0.61 
(0.44–
0.84) 
0.84 
(0.62–
1.13) 
0.87 
(0.59-
1.28) 
0.80 
(0.61-
1.04) 
50-80 0.93 
(0.70–
1.23) 
0.68 
(0.50–
0.92) 
0.85 
(0.67-
1.08) 
0.74 
(0.56-
0.97) 
0.76 
(0.62–
0.94) 
0.91 
(0.75–
1.11) 
0.73 
(0.56-
0.96) 
0.77 
(0.62-
0.94) 
<50 0.85 
(0.59–
1.24) 
0.56 
(0.37–
0.85) 
0.88 
(0.65-
1.19) 
0.79 
(0.55-
1.14) 
0.99 
(0.77–
1.28) 
1.01 
(0.79–
1.30) 
0.84 
(0.58-
1.23) 
0.50 
(0.38-
0.66)‡ 
Symptomatic Yes  0.99 0.75 0.93 0.55 0.83 0.79 0.76 0.81 
 HF32,71,72 (0.69-
1.42) 
(0.51-
1.10) 
(0.75-
1.15) 
(0.34–
0.91) / 
0.98 
(0.65–
1.49) # 
(0.64-
1.09) 
(0.60-
1.03) 
(0.59-
0.98) 
(0.58–
1.14) / 
0.62 
(0.44–
0.88)¶ 
No 0.86 
(0.67-
1.09) 
0.61 
(0.47-
0.79) 
0.81 
(0.63-
1.04) 
0.74 
(0.57–
0.96) 
0.79 
(0.67-
0.94) 
0.99 
(0.84-
1.16) 
0.83 
(0.62-
1.11) 
0.77 
(0.62–
0.94) 
Prior history of 
stroke/TIA73-75 
Yes 0.84 
(0.58–
1.20) 
0.75 
(0.52–
1.08) 
0.94 
(0.77–
1.16) 
0.76 
(0.56–
1.03) 
0.66 
(0.48–
0.90) 
1.01 
(0.77–
1.34) 
0.97 
(0.79–
1.19) 
0.73 
(0.55–
0.98) 
No 0.93 
(0.73–
1.18) 
0.60 
(0.45–
0.78) 
0.77 
(0.58–
1.01) 
0.82 
(0.65–
1.03) 
0.85 
(0.72–
0.99) 
0.91 
(0.77–
1.06) 
1.11 
(0.92–
1.34) 
0.68 
(0.58–
0·80) 
Prior use of 
VKAs30,32,81 
VKA-
experien
ced 
0.87 
(0.66-
1.14) 
0.67 
(0.50-
0.90) 
0.97 
(0.78-
1.19) 
0.73 
(0.57, 
0.95) 
0.75 
(0.61-
0.92) 
0.93 
(0.77-
1.12) 
0.84 
(0.66-
1.08) 
0.66 
(0.55, 
0.80) 
VKA-
naïve 
0.94 
(0.71-
1.25) 
0.64 
(0.47-
0.88) 
0.76 
(0.59-
0.98) 
0.86 
(0.67, 
1.11) 
0.88 
(0.73-
1.07) 
0.95 
(0.78-
1.15) 
0.72 
(0.53-
0.97) 
0.73 
(0.59, 
0.91) 
Antiplatelet 
agents 
concomitantly
32,76,77 
Yes 0.93 
(0.70-
1.25) 
0.8 
(0.59-
1.08) 
NA 0.58 
(0.39-
0.85) 
** 
0.82 
(0.67-
1.0) 
0.93 
(0.76-
1.12) 
NA 0.77 
(0.60-
0.99) 
** 
No 0.87 
(0.66-
1.15) 
0.52 
(0.38-
0.72) 
NA 0.84 
(0.66-
1.07) 
** 
0.79 
(0.64-
0.96) 
0.94 
(0.78-
1.15) 
NA 0.65 
(0.55-
0.78) 
** 
Centre 
average TTR78-
80 
<LQ 1.00 
(0.68–
1.45) 
0.57 
(0.37–
0.88) 
0.70 
(0.47-
1.04) 
0.73 
(0.53–
1.00) 
0.65 
(0.48–
0.89) 
0.71 
(0.52–
0.96) 
0.80 
(0.66-
0.98) 
0.50 
(0.36-
0.70) 
LQ-Me 0.81 
(0.56–
1.17) 
0.50 
(0.33–
0.77) 
0.90 
(0.64-
1.26) 
0.94 
(0.67-
1.31) 
0.82 
(0.63–
1.06) 
0.81 
(0.62–
1.05) 
0.96 
(0.81-
1.14) 
0.64 
(0.48-
0.86) 
Me-UQ 0.89 
(0.58–
1.36) 
0.69 
(0.44–
1.09) 
0.88 
(0.62-
1.25) 
0.64 
(0.42-
0.97) 
0.83 
(0.62–
1.11) 
1.13 
(0.87–
1.48) 
1.03 
(0.87-
1.22) 
0.85 
(0.65-
1.11) 
>UQ 0.92 
(0.59–
1.45) 
0.95 
(0.61–
1.48) 
0.73 
(0.50-
1.06) 
0.88 
(0.57–
1.35) 
0.90 
(0.67–
1.21) 
1.16 
(0.88–
1.54) § 
1.25 
(1.10-
1.41) § 
0.75 
(0.58-
0.97) 
Patients who 
underwent 
cardioversion during 
follow-up84-86 
1.28 
(0.35–
4.76) 
0.49 
(0.09–
2.69) 
1.38 
(0.61–
3.11) †† 
No 
events 
2.82 
(0.90–
8.82) 
0.99 
(0.25–
3.93) 
1.51 
(1.12–
2.05) †† 
Only 2 
events
, one 
in 
each 
group 
 * hazard ratios  for edoxaban according to different subgroups were published as forest 
plots only 
† major or clinically relevant non-major bleeding 
‡ for age subgroups <65 / 65 to <75 years 
§ significant interaction between subgroups 
¶ for CHADS2 score 3/4/5/6 
# HF with reduced ejection fraction / HF with preserved ejection fraction 
** Patients on aspirin ≥165 mg per day and those who required treatment with both aspirin 
and a P2Y12 receptor antagonist at baseline were not eligible to be enrolled in ARISTOTLE 
†† cardioversion and catheter ablation of AF in total  
CrCl, creatinine clearance; HF, heart failure; LQ, low quartile; Me, median; NA, data not 
available; TIA, transient ischaemic attack; UQ, upper quartile; VKA, vitamin K antagonists 
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